Login / Signup

Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study.

Hiroshi MukaeHiroshi YotsuyanagiNorio OhmagariYohei DoiHiroki SakaguchiTakuhiro SonoyamaGenki IchihashiTakao SanakiKeiko BabaYuko TsugeTakeki Uehara
Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)
Ensitrelvir treatment demonstrated a favorable antiviral efficacy and potential clinical benefit with an acceptable safety profile.
Keyphrases
  • placebo controlled
  • double blind
  • coronavirus disease
  • sars cov
  • open label
  • clinical trial
  • phase ii
  • randomized controlled trial
  • risk assessment
  • combination therapy
  • respiratory syndrome coronavirus